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Abstract Glutaminyl cyclase (QC) is responsible for the
presence of pyroglutamyl residues in many neuroendocrine
peptides. An examination of the bovine tissue distribution of
QC immunoreactivity, enzyme activity, and mRNA confirmed
that QC was abundant in brain and pituitary by all three
measures. However, enzymatic activity was considerably more
widespread than either immunoreactivity or mRNA, suggesting
multiple enzyme forms. Partially purified QC from bovine spleen
differed significantly from the known bovine pituitary QC in
physical and catalytic properties. We propose that this form of
glutaminyl cyclase plays a role in the posttranslational proces-
sing of constitutively secreted pGlu-containing proteins.
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1. Introduction
Mammals contain numerous secretory peptides and pro-
teins possessing an amino-terminal pyroglutamyl (pGlu) resi-
due. Hormones such as the thyrotropin-releasing hormone
and gonadotropin-releasing hormone, and neurotransmitters
such as neurotensin are representative peptides whose amino-
terminus is blocked by this residue. This posttranslational
modi¢cation is catalyzed in vivo by glutaminyl cyclase (QC,
EC 2.3.2.5) [1,2] which acts upon the glutaminyl residues un-
masked by prohormone convertase cleavage of precursor pep-
tides [3]. Subcellular distribution studies have con¢rmed the
presence of glutaminyl cyclase in pituitary secretory granules
[4] and cytochemical studies in anterior pituitary have local-
ized QC protein and mRNA exclusively to somatotrophs [5].
The bovine and human pituitary QC cDNA have been se-
quenced and found to encode a 361 amino acid protein with
a 27 amino acid endoplasmic reticulum signal [6,7]. Northern
blotting of mRNA derived from a variety of bovine tissues
revealed a single 2.1 kb species of QC mRNA in all reactive
tissues [6] with high levels in brain tissues.
The expression of spleen QC was not initially detected in
the Northern blot by Spiess and coworkers [6]. However, be-
cause of the presence of the pyroglutamyl group in IgG, those
authors speculated that spleen may contain an alternative
form of QC. This suggestion was strengthened by the report
by Kizer and coworkers [1] of QC in rat B lymphocytes. It
was the purpose of this study to examine the possibility of
multiple forms of QC in bovine tissues and, in particular, to
determine if spleen indeed contains a form of glutaminyl cy-
clase which di¡ers from that found in pituitary.
2. Materials and methods
2.1. Tissue distribution
For the bovine tissue distribution the tissues were extracted in the
presence of protease inhibitors and separated into soluble and mem-
brane fractions by the method of May et al. [8]. Protein was deter-
mined with the Coomassie Plus reagent from Pierce using bovine
serum albumin as a standard. Enzymatic activity of tissue extracts
was determined with the dansylated pre-neurotensin fragment
HPLC assay of Consalvo et al. [9]. Western blotting was performed
with antibodies raised against an amino-terminal peptide derived from
the bovine pituitary QC sequence [7].
2.2. Partial puri¢cation and characterization of bovine spleen
glutaminyl cyclase
Twenty grams of tissue was removed from a frozen mature bovine
spleen and minced with a razor blade. The tissue sample was homo-
genized in a Waring blender with ¢ve volumes of chilled 0.02 M
potassium phosphate bu¡er, pH 6.5, subjected to two freeze/thaw
cycles, and centrifuged for 30 min at 36 300Ug. The supernatant
pH was lowered to 5 via the dropwise addition of 0.1 M acetic
acid; the solution was stirred for an additional 15 min, and then
centrifuged as before. The pH of the supernatant pool was brought
to 7.0 by dropwise addition of 1 M K3PO4. The extract was then
fractionated with ammonium sulfate and the 50^65% fraction retained
for dialysis against 0.02 M MOPS, pH 7.2, containing 0.1 M NaCl
and 5% glycerol. The dialysate was clari¢ed by centrifugation and
diluted ¢ve fold with 0.02 M MOPS, pH 7.2, immediately prior to
chromatography on a DE52 cellulose (Whatman) column (1.5U10
cm) equilibrated with the same bu¡er. The column was washed with
¢ve column volumes of equilibration bu¡er and eluted with a 20
column volume salt gradient from 0 M to 0.5 M NaCl. Active frac-
tions were pooled, precipitated with 70% ammonium sulfate, and
dialyzed as before. The puri¢ed enzyme passed unhindered through
both concanavalin A Sepharose and lentil lectin Sepharose columns at
pH 7.2 without even residual activity eluted with methyl mannose. Gel
¢ltration chromatography of the puri¢ed spleen preparation was ac-
complished with a Sephacryl S-200 column (1.5U40 cm) calibrated
with bovine serum albumin, horseradish peroxidase, carbonic anhy-
drase and myoglobin.
Enzymatic activity was measured during spleen QC puri¢cation and
characterization by a modi¢cation of the method of Bateman [10] in
which the bu¡er was 0.1 M sodium borate, pH 8.5, and the substrate
was glutaminamide (Bachem). For the substrate speci¢city study Gln-
X peptides (Bachem) were substituted for glutaminamide.
3. Results
Fig. 1 shows that the initial tissue distribution study of QC
mRNA by Pohl and coworkers [6] correlated relatively well
with Western blot and enzyme activity analysis of the various
brain tissues. The Western blot (Fig. 2) showed two primary
immunoreactive species, a 40 kDa protein found exclusively in
the soluble pituitary extract and a 32 kDa band found in the
soluble fraction of all tissues which showed immunoreactivity.
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Although the larger pituitary QC band is intense, the speci¢c
activity of the pituitary extract is surprisingly low in compar-
ison to the brain extracts. This may indicate a form of acti-
vation of QC via proteolytic processing. The antibody is di-
rected towards the amino-terminus, suggesting that the
di¡erence in the two immunoreactive proteins lies in proteo-
lytic cleavage within a hydrophilic region approximately 80
amino acids from the carboxy-terminus which probably rep-
resents an exposed surface loop.
Further examination of Fig. 1 reveals marked discrepancies
between the three measures of expression. For example, spleen
showed neither immunoreactivity nor mRNA expression even
though the spleen extract contained enzymatic speci¢c activity
approximately equivalent to that of pituitary. Fractionation
of the spleen QC activity with ammonium sulfate at 0‡C re-
vealed that the activity remained soluble until the saturation
level reached 50% while pituitary QC precipitated at 30%
saturation [9]. Anion exchange chromatography following
ammonium sulfate precipitation resulted in the elution of en-
zyme activity in a single peak at a salt concentration of ap-
proximately 0.22 M. The resulting enzyme preparation was
highly active and stable at 4‡C for several weeks. Gel ¢ltration
of the concentrated pool yielded a peak of activity corre-
sponding to a molecular weight of 48 500 Da. This is notably
higher than the 38 000 Da reported for the bovine pituitary
enzyme [4,6].
Testing of the puri¢ed spleen QC action upon a series of
Fig. 1. Distribution of glutaminyl cyclase in bovine tissues. Compar-
ison of Northern blot, Western blot and enzyme-speci¢c activity.
Lanes are Th-thymus, Hi-hippocampus, Hy-hypothalamus, Ki-kid-
ney, St-striatum, Ad-adrenal, Sp-spleen, AP-anterior pituitary, Td-
thyroid. Speci¢c activity measurements are the means of at least
four determinations with an error of less than 18% in all lanes.
Fig. 2. Western blot analysis of bovine tissue soluble extracts. Lanes
are Pi-pituitary, Ad-adrenal, Ki-kidney, Sp-spleen, St-striatum, Hy-
hypothalamus, Hi-hippocampus, Td-thyroid, Th-thymus. Four mi-
crograms of protein were loaded in each lane. The 50 kDa band in
lanes Pi and Ki was also observed in preimmune controls and is
presumed to be an artifact.
Table 1
Substrate speci¢city for partially puri¢ed spleen QC at pH 8.5 and
37‡C
Substrate Speci¢c activity
(nmol/min/mg)
Relative activity
(%)
Gln-NH2 28.5 þ 0.6 100.0
Gln-Gln-Gln 16.4 þ 0.3 57.5
Gln-Gly 12.4 þ 0.3 43.5
Gln-Gly-Pro 11.4 þ 0.6 40.0
Gln-Ala 10.6 þ 0.8 37.2
Gln-Glu 9.3 þ 0.5 32.6
Gln-Gln 6.4 þ 0.6 22.5
D-Gln Negligible ^
L-Gln Negligible ^
Substrate concentration was 3 mM (n = 3, mean þ S.D.). Unless oth-
erwise noted, all amino acids are the L isomers.
Fig. 3. Dependence of enzymatic activity of bovine spleen QC
(squares) and recombinant human pituitary QC [22] (asterisks) on
pH. Activities were normalized for comparison. Glutaminamide (5
mM) was the substrate and MOPS (6.0^8.0), EPPS (7.0^9.0) and
borate (8.0^10.0) were substituted for the bu¡er in the standard
protocol [10].
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Gln-X peptides (Table 1) revealed that glutaminamide was the
optimal substrate. In contrast to the pituitary enzyme [7,10],
Gln-Gln proved to be the least e¡ective substrate. As ex-
pected, neither of the free amino acid isomers of glutamine
showed detectable reaction. Spleen QC exhibited maximal en-
zyme activity at pH 8.5, an alkaline shift of one unit when
compared to the pH optimum of the pituitary enzyme (Fig. 3).
4. Discussion
The tissue distribution of QC enzymatic activity indicated
the presence of QC in every tissue examined. As predicted by
the lack of a membrane-anchoring domain in the known ami-
no acid sequence of glutaminyl cyclase, enzyme activity and
immunoreactivity were exclusively found in the soluble frac-
tions of the tissue extracts. This is in contrast to the numerous
membrane-bound forms of another peptide terminus-modify-
ing enzyme, peptidyl-glycine K-amidating monooxygenase
(PAM) [8]. Likewise, thymus and spleen exhibited high QC-
speci¢c activity whereas these tissues contain little, if any,
PAM activity or mRNA [11^13]. These observations are con-
sistent with the absence of known amidated peptides produced
by thymus and spleen as well as the presence of several pro-
teins of the immune system which contain the pyroglutamyl
group including both the heavy [14,15] and light chains [16] of
immunoglobulins; the J chains of polymeric IgA and IgM
[17]; the C1q subcomponent of the classical complement path-
way [18]; and human interferon [19].
Because of the lack of pituitary QC mRNA and immuno-
reactivity in spleen and the presence of the pyroglutamyl res-
idue on proteins rather than peptides in this tissue, we decided
to examine the glutaminyl peptide cyclizing activity in spleen.
Partial puri¢cation of QC activity from soluble spleen extracts
yielded an enzyme fraction with a speci¢c activity comparable
to the pituitary glutaminyl cyclase after anion exchange chro-
matography [10]. The partially puri¢ed enzyme was stable
upon storage at 4‡C and appeared to di¡er from its pituitary
counterpart in terms of size, pH optimum for activity, sub-
strate speci¢city, and solubility in ammonium sulfate. The
inability of the spleen QC to adsorb to immobilized lectins,
also in contrast to reports of pituitary QC [1], suggested that
it is not highly glycosylated. A ¢nal biochemical di¡erence
between the spleen and pituitary enzymes is the lack of dis-
cernible inhibition of the spleen QC by imidazole at concen-
trations considerably higher than those required for inhibition
of pituitary QC (J.S. Temple and R.C. Bateman, Jr., manu-
script in preparation). In sum, spleen and pituitary QC appear
to have distinctly di¡erent physical and catalytic properties.
The genetic origin of the various QC forms in unclear.
Other neuroendocrine biosynthetic enzymes such as PAM
[20] and dopamine L-hydroxylase [21] are expressed as tis-
sue-speci¢c forms derived from a single gene. It is quite pos-
sible that all bovine glutaminyl cyclases are derived also from
a single gene and, in fact, a single pituitary QC gene has been
localized to human chromosome 2 (RH map A002E27; Uni-
Gene Hs. 79033). However, another very real possibility is
that the spleen QC is the product of a second gene of low
homology to the one encoding the pituitary enzyme. This
would be consistent with the absence of spleen QC mRNA
in the Northern blot and our inability in multiple attempts to
amplify spleen QC cDNA using RT-PCR and primers which
consistently work well with mRNA from pituitary and hypo-
thalamus [7,22]. The solution of this mystery will have to
await complete puri¢cation and peptide sequencing of the
spleen QC.
The presence of several constitutively expressed pGlu-con-
taining proteins in the spleen indicates a need for glutaminyl
cyclase activity in the constitutive secretory pathway. The en-
zyme reported here is a likely candidate for this role as evi-
denced by its relative abundance in spleen and a pH activity
optimum which makes its action in the acidic environment of
a neuroendocrine secretory granule di⁄cult to envision. Also,
as evidenced by its solubility in the acid precipitation step of
the puri¢cation procedure, spleen glutaminyl cyclase does not
aggregate at low pH like proteins directed to the regulated
secretory pathway [23,24]. It appears likely, therefore, that
the role of this novel form of QC is to catalyze pyroglutamyl
residue formation at the amino-terminus of proteins secreted
through the constitutive pathway.
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